In March, Marina Litvin, MD and collaborators published research titled the “Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis,” in the “Journal of Cystic Fibrosis.”
The study’s purpose was to bring definition to the effect that elexacaftor-tezacaftor-ivacaftor (ETI) has on body weight, body mass index (BMI), blood pressure, lipids and glycemic control.
ETI is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator which helps regulate the proper flow of cell membranes in the lungs and other organs. In some clinical trials involving CFTR modulators, weight gain has been reported.
Litvin and colleagues used various methods in their research, concluding that “in this single-center, retrospective, observational study of 134 adults with cystic fibrosis, initiation of ETI was associated with increases in BMI at a mean follow up of 12.2 months. Changes in other cardiometabolic risk factors were also observed. Widespread use of ETI may be expected to increase the incidence of overnutrition in the cystic fibrosis population.”